It was a busy week for the biotech sector as usual, with lots of regulatory and pipeline updates, before the first-quarter ...

H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial ...

Edgewise Therapeutics, Inc.’s EWTX share price has surged by 7.97%, which has investors questioning if this is right time to sell.